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EASEL Study: Sodium Glucose Cotransporter 2 
Inhibitors (SGLT2i) Confer a Lower Rate of All-
Cause Mortality, Hospitalization for Heart Failure 
(HF), and Major Adverse Cardiovascular Events 
(MACE)  
After propensity matching, 25 258 patients were 
followed for a median of 1.6 years. Compared with non-
SGLT2i, initiation of SGLT2i was associated with a lower 
rate of all-cause mortality and hospitalization for HF (1.73 
vs 3.01 events per 100 person-years; HR, 0.57) and MACE 
(2.31 vs 3.45 events per 100 person-years; HR, 0.67). 
SGLT2i initiation was also associated with an ≈2-fold 
higher risk of below-knee lower extremity amputation 
(0.17 vs 0.09 events per 100 person-years; HR, 1.99). 
Because of the disproportionate canagliflozin exposure in 
the database, the majority of amputations were observed 
on canagliflozin (Udell JA et al, Circulation 
2018;137:1450-9).   
In Most Young Patients Who Experienced Sudden 
Cardiac Arrest (SCA), Sports was a Trigger in a 
Minority of Cases, while Standard Cardiovascular 
Risk Factors were Found in Over Half of them 
Among 186 SCAs in the young (ages 5-34 years) (5% 
of all SCAs), overall prevalence of warning signs before 
SCA was low (29%), and 26 (14%) were associated with 
sports as a trigger. The remainder (n=160) occurred in 
other settings categorized as non-sports. Sports-related 
SCAs accounted for 39% of SCAs in patients aged ≤18, 
13% of SCAs in patients aged 19 to 25, and 7% of SCAs 
in patients aged 25 to 34. Sports-related SCA cases were 
more likely to present with shockable rhythms, and 
survival from cardiac arrest was 2.5-fold higher in sports-
related vs non-sports SCA (28% vs 11%; P=0.05). Overall, 
the most common SCA-related conditions were sudden 
arrhythmic death syndrome (31%), coronary artery disease 
(22%), and hypertrophic cardiomyopathy (14%). There 
was an unexpectedly high overall prevalence of 
established cardiovascular risk factors (obesity, diabetes 
mellitus, hypertension, hyperlipidemia, smoking) with ≥1 
risk factors in 58% of SCA cases (Jayaraman R et al, 
Circulation 2018;137:1561-1570).   
Although Second Arterial Conduit Use May be Low 
and Declining, Arterial Grafts are Associated With 
Lower Mortality and Fewer Cardiovascular Events / A 
Right Internal Mammary Artery (IMA) Graft Offers 
no Benefit Over That of a Radial Artery, But did 
Increase Risk of Sternal Wound Infection / Thus, the 
Radial Artery May be the Preferred Second Conduit  
The study included patients who received second 
arterial (right IMA or radial artery, n=5866) or a venous 
conduit (n=53 566). Propensity score matching yielded 
5813 matched sets. Subgroup analysis compared outcomes 
between propensity score–matched recipients of a right 
IMA (n=1576) or a radial artery (n=4290). Use of second 
arterial conduit use decreased from 10.7% in 2006 to 9.1% 
in 2011 (P<0.0001). However, receipt of a second arterial 
conduit was associated with lower mortality (13.1% vs 
10.6% at 7 years; hazard ratio-HR, 0.79), and lower risks 
of MI (HR, 0.78) and repeat revascularization (HR, 0.82). 
In comparison with radial artery grafts, right IMA grafts 
were associated with similar mortality rates (10.3% vs 
10.7% at 7 years; HR, 1.10) and individual risks of 
cardiovascular events, but the risk of sternal wound 
infection was increased (risk difference, 1.07%) 
(Goldstone AB et al, Circulation 2018;137:1698-1707).  
RADIAL: Use of Radial-Artery vs Saphenous Vein 
Grafts (SVG) for CABG Resulted in a Lower Rate of 
Adverse Cardiac Events and a Higher Rate of Patency 
at 5 Years of Follow-Up  
Analysis of 6 trials comprising 1036 patients (534 with 
radial-artery grafts and 502 with SVGs) indicated that over 
5+2.5 years, adverse cardiac events were fewer with radial-
artery grafts than with SVGs (hazard ratio-HR, 0.67; 
p=0.01). At follow-up angiography, use of radial-artery 
grafts was associated with a lower risk of occlusion (HR, 
0.44; p<0.001). Use of radial-artery grafts was associated 
with a lower incidence of MI (HR, 0.72; p=0.04) and of 
repeat revascularization (HR, 0.50; p<0.001) but not of 
death from any cause (HR, 0.90; p=0.68) (Gaudino M et 
al, N Engl J Med 2018; 378:2069-77).   
CREATIVE Trial: In Patients With Low Responsive-
ness to Clopidogrel (According to Thrombo-
elastography), Adjunctive Use of Cilostazol Improved 
Clinical Outcomes Without Increasing Risk of Major 
Bleeding / Decreased Trend of Negative Outcomes 
With Double Dosage of Clopidogrel  
Using thromboelastography, 1078 patients undergoing 
percutaneous coronary intervention (PCI) at high 
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thrombotic risk were selected and the intensified 
antiplatelet therapies with standard antiplatelet therapy 
were compared. The primary end point (major adverse 
cardiac and cerebrovascular events at 18 months after PCI) 
occurred in 52 patients (14.4%) in the standard 
(conventional strategy) group, 38 patients (10.6%) in the 
double (double-dose clopidogrel) group, and 30 patients 
(8.5%) in the triple (adjunctive cilostazol) group (hazard 
ratio-HR, 0.72, double vs standard; HR, 0.55, triple vs 
standard). No significant difference in the rates of major 
bleeding was found in the double group (3.34% vs 1.93% 
in standard, P=0.133) and the triple group (2.53% vs 
1.93% in standard, P=0.240). The rate of minor bleeding 
increased in the double group (27.4% vs 20.3% in 
standard, P=0.031), but not in the triple group (23.6% vs 
20.3% in standard, P=0.146) (Tang Y-D et al, Circulation 
2018;137:2231-2245).  
MOMENTUM 3: A Fully Magnetically Levitated 
Centrifugal-Flow Pump was Superior to a Mechanical-
Bearing Axial-Flow Pump With Regard to Survival 
Free of Disabling Stroke or Reoperation to Replace or 
Remove a Malfunctioning Device 
Of 366 patients with advanced heart failure, 190 were 
assigned to the centrifugal-flow pump group and 176 to the 
axial-flow pump group. In the intention-to-treat 
population, the primary end point (survival at 2 years free 
of disabling stroke or of reoperation to replace or remove 
a malfunctioning device) occurred in 151 patients (79.5%) 
in the centrifugal-flow pump group and in 106 (60.2%) in 
the axial-flow pump group (P<0.001 for noninferiority; 
hazard ratio-HR, 0.46; P<0.001 for superiority]). 
Reoperation for pump malfunction was less frequent in the 
centrifugal-flow pump group than in the axial-flow pump 
group (3 patients or 1.6% vs 30 patients or 17%; HR, 0.08; 
P<0.001). The rates of death and disabling stroke were 
similar in the two groups, but the overall rate of stroke was 
lower in the centrifugal-flow pump group than in the axial-
flow pump group (10.1% vs 19.2%; HR, 0.47, P=0.02). 
(Mehra MR et al, N Engl J Med 2018;378:1386-95).   
CABANA: Catheter Ablation for Atrial Fibrillation 
(AF) Not Superior to Drug Therapy 
Among 2,204 AF patients (median age 68 years), 
randomized to drugs (n=1096, 49.7%) or pulmonary vein 
isolation (PVI) (n=1108), over a median of ~4 years, in an 
intention-to-treat analysis, the primary endpoint (death, 
disabling stroke, serious bleeding, or cardiac arrest) 
occurred in 89 patients (8%) randomized to ablation and 
101 patients (9.2%) randomized to drugs (hazard ratio-HR 
0.86, p=NS). Also, none of the components of the primary 
endpoint differed significantly (www.acc.org/latest-in-
cardiology/clinical-trials/2018/05/10/15/57/cabana).  
 
REPRISE III: Lotus (a Mechanically Expanded) Valve 
Had Significantly Greater Freedom from Moderate or 
Severe Paravalvular Leak and Smaller Valve Area / 
Higher Gradients than (Self-Expanding) Corevalve, 
but with no Clinical Differences in the Composite End 
Point (Mortality, Disabling Stroke, and Moderate 
Paravalvular Leak) or in Quality of Life at 1 Year   
Among 912 patients with extreme- and high-risk aortic 
stenosis (median age 84, 51% women, STS score 6.8±4.1) 
randomly assigned (2:1 ratio; 607 Lotus:305 CoreValve), 
CoreValve demonstrated lower gradients and larger aortic 
valve area and Doppler velocity index than Lotus at 
discharge; the difference decreased in subsequent follow-
up up to a year (all p<0.01). Lotus had lower rates of 
paravalvular leak that persisted over time (p<0.05). Similar 
outcomes were seen when comparing each valve type by 
size group (small, medium, large). These differences did 
not translate into worse clinical outcomes (Asch FM et al, 
Circulation 2018:137:2557-67).   
Elderly ACS 2: Elderly Patients With Acute Coronary 
Syndromes (ACS) Showed no Difference in the 
Primary End Point Between Reduced-Dose (5 mg) 
Prasugrel and Standard-Dose Clopidogrel  
Among 1443 elderly (>74 years) ACS patients 
undergoing PCI enrolled in a study (interrupted early 
because of futility) comparing a once-daily maintenance 
dose of prasugrel 5 mg with the standard clopidogrel 75 
mg, the primary end point (mortality, MI, disabling stroke, 
and rehospitalization for cardiovascular causes or 
bleeding) occurred in 121 patients (17%) with prasugrel 
and 121 (16.6%) with clopidogrel (hazard ratio, 1.007; 
p=0.955). Definite/probable stent thrombosis rates were 
0.7% with prasugrel vs 1.9% with clopidogrel (odds ratio-
OR, 0.36; p=0.06). Bleeding rates were 4.1% with 
prasugrel vs 2.7% with clopidogrel (OR, 1.52; p=0.18). 
(Savonitto S et al, Circulation 2018;137:2435-45).   
SWAP-4: De-Escalation from Ticagrelor to 
Clopidogrel is Associated with an Increase in Platelet 
Reactivity / The Use of a Loading Dose Before the 
Initiation of a Maintenance Dose of Clopidogrel 
Mitigates these Observations   
This study was conducted in patients on maintenance 
dosing (MD) of aspirin (81 mg/d) and clopidogrel (75 
mg/d). After a 7-day run-in with ticagrelor (180 mg 
loading dose [LD] followed by 90 mg bid MD), patients 
(n=80) were randomized into 1 of 4 groups: group A, 
clopidogrel 600 mg LD 24 h after the last MD of ticagrelor 
(C-600 mg-24h); group B, clopidogrel 600 mg LD 12 h 
after the last MD of ticagrelor (C-600 mg-12h); group C, 
clopidogrel 75 mg/d MD 24 h after the last MD of 
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ticagrelor (C-75 mg-24h); and group D, ticagrelor 90 mg 
bid MD (T-90 mg twice daily). MD of the randomized 
treatment was maintained for 10±3 days. Pharmaco-
dynamic assessments were performed by VerifyNow.  
T-90 mg bid led to lower platelet reactivity than any 
clopidogrel regimen. P2Y12 reaction unit levels were 
similar between the C-600 mg-24h (group A) and the C-75 
mg-24h (group C) (p=0.29), including at 48 hours. P2Y12 
reaction unit levels were lower with C-600 mg-12h (group 
B) than with C-75 mg-24h (group C; p=0.024). Maximal 
platelet aggregation over time was lower with both C-600 
mg-24h (group A; p=0.041) and C-600 mg-12h (group 
B; P=0.028) compared with C-75 mg-24h (group C). 
There were no pharmacodynamic differences for all tests 
between C-600 mg-24h (group A) and C-600 mg-12h 
(group B). In group C (C-75 mg-24h), platelet reactivity 
increased compared with baseline as early as 24 hours, 
reaching statistical significance at 48 and 72 hours and up 
to 10 days. These pharmacodynamic findings were delayed 
and blunted in magnitude with the administration of an LD. 
(Franchi F et al, Circulation 2018;137:2450-62).   
Registry Data: Use of VF Conversion Testing (CT) 
after Subcutaneous (S-ICD) Implantation, Performed 
in ~71%, was not Associated With a Composite of In-
hospital Complications or Death / Insufficient Safety 
Margin (ISM) was Relatively Uncommon (~7%)  
Ventricular fibrillation (VF) conversion testing (CT) 
was performed in 70.7% (n=5624) of 7960 patients with S-
ICDs. Although deferral of CT was associated with several 
patient characteristics, the facility effect was 
comparatively more important. An insufficient safety 
margin (ISM) (defined as VF conversion energy >65J) 
during testing, occurred in 6.9% (n=336) of 4864 patients 
without a prior ICD and was more common among white 
patients and those with ventricular pacing on the 
preimplant ECG, higher preimplant blood pressure, larger 
body surface area, higher body mass index, and lower 
ejection fraction. A risk score was able to identify patients 
at low (<5%), medium (5% to 10%), and high risk (>10%) 
for ISM. CT testing was not associated with a composite 
of inhospital complications including death (Friedman DJ 
et al, Circulation 2018;137:2463-77).   
Ambulatory Blood-Pressure (BP) Measurements: A 
Stronger Predictor of All-Cause and Cardiovascular 
(CV) Mortality than Clinic BP Measurements / White-
Coat Hypertension Not Benign / Masked Hypertension 
Associated with a Greater Risk of Death than Sustained 
Hypertension  
Analyzed data from a registry-based, multicenter, 
national cohort including 63,910 adults followed-up for 
4.7 years (3808 deaths from any cause / 1295 of these from 
CV causes), indicated that 24-hour systolic BP was more 
strongly associated with all-cause mortality (hazard ratio-
HR, 1.58 per 1-SD increase in BP) than the clinic systolic 
BP (HR, 1.02). Corresponding hazard ratios per 1-SD 
increase in pressure were 1.55 for nighttime ambulatory 
systolic BP and 1.54 for daytime ambulatory systolic BP. 
These relationships were consistent across subgroups of 
age, sex, and status with respect to obesity, diabetes, 
cardiovascular disease, and antihypertensive treatment. 
Masked hypertension was more strongly associated with 
all-cause mortality (HR, 2.83) than sustained hypertension 
(HR, 1.80) or white-coat hypertension (HR, 1.79). Results 
for CV mortality were similar to those for all-cause 
mortality (Banegas JR et al, N Engl J Med 2018; 378:1509-
20).  
 
EXTEND-IA TNK: Tenecteplase Before 
Thrombectomy is Associated With a Higher Incidence 
of Reperfusion and Better Functional Outcome Than 
Alteplase Among Patients With Ischemic Stroke 
Treated Within 4.5 Hours After Symptom Onset 
 
Among 202 stroke patients, 101 assigned to receive 
tenecteplase and 101 to alteplase, the primary outcome 
(reperfusion of >50% of the involved ischemic territory or 
an absence of retrievable thrombus at time of initial 
angiographic assessment) occurred in 22% of tenecteplase 
patients vs 10% of alteplase patients (p=0.002 for 
noninferiority; p=0.03 for superiority). Tenecteplase 
resulted in a better 90-day functional outcome than 
alteplase (p=0.04). Symptomatic intracerebral hemorrhage 
occurred in 1% of patients in each group (Campbell BCV 
et al, N Engl J Med 2018; 378:1573-1582).   
NAVIGATE ESUS: Rivaroxaban is not Superior to 
Aspirin in the Prevention of Recurrent Stroke After an 
Initial Embolic Stroke of Undetermined Source (ESUS) 
and is Associated With Higher Risk of Bleeding 
Among 7213 patients with recent ischemic stroke 
(ESUS), 3609 randomly assigned to rivaroxaban (15 mg 
qd) and 3604 to aspirin (100 mg qd), over a median of 11 
months, the primary efficacy outcome (first recurrence of 
ischemic or hemorrhagic stroke or systemic embolism) 
occurred in 172 patients in the rivaroxaban group 
(annualized rate, 5.1%) and in 160 in the aspirin group 
(annualized rate, 4.8%) (hazard ratio - HR, 1.07; p=0.52). 
Recurrent ischemic stroke occurred in 158 patients in the 
rivaroxaban group (annualized rate, 4.7%) and in 156 in 
the aspirin group (annualized rate, 4.7%). Major bleeding 
occurred in 62 patients in the rivaroxaban group 
(annualized rate, 1.8%) and in 23 in the aspirin group 
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(annualized rate, 0.7%) (HR, 2.72; p<0.001) (Hart RG et 
al, N Engl J Med 2018; 378:2191-2201).  
GARY Registry: The Incidence of Pacemaker 
Implantation and Disabling Stroke Was Higher With 
Rapid (RDVs) vs Conventional Deployment Valves 
(CBVs), With no Beneficial Effect on In-Hospital 
Mortality / The 3 RDVs Presented Different 
Complication Profiles With Regard to Pacemaker 
Implantation and Transvalvular Gradients 
Among 22,062 patients undergoing isolated surgical 
aortic valve replacement (AVR), 20,937 patients received 
a CBV, whereas 1,125 patients were treated with an RDV 
with significantly reduced procedure with use of RDV 
(160 vs 150 min; p< 0.001), cardiopulmonary bypass (83 
vs 70 min; p< 0.001), and aortic cross clamp times (60 vs 
44 min; p< 0.001), but RDVs showed significantly 
elevated rates of pacemaker implantation (3.7% vs 8.8%; 
p< 0.001) and disabling stroke (0.9% vs 2.2%; p< 0.001), 
whereas in-hospital mortality was similar (1.7% vs 2.2%; 
p=0.22). These findings persisted after 1:1 propensity 
score matching. Comparison of the 3 RDVs, the self-
expanding, nitinol-based 3F Enable valve (Medtronic) 
(n=162) (has been withdrawn from the market), the 
balloon expandable INTUITY valve (Edwards) (n=466), 
and the Perceval sutureless valve (Sorin/LivaNova) 
(n=900), revealed nonsignificant different pacemaker rates 
(~8-14%) and significantly different post-operative 
transvalvular gradients (21% of Perceval with gradient >20 
mmHg) (Ensminger S et al, J Am Coll Cardiol 
2018;71:1417–28).   
Delayed Coronary Obstruction (DCO) Following 
TAVI is a Rare (0.22%) Phenomenon, Mostly 
Occurring Within 24h but Also >2 Months, More 
Commonly After Valve-in-Valve Procedures & with 
the Self-Expanding Valves, & Associated With High 
In-Hospital Mortality Rate 
38 DCO (incidence 0.22%) cases were identified from 
a total of 17,092 TAVR procedures, occurring more 
commonly after valve-in-valve procedures (0.89% vs. 
0.18%; p< 0.001) and if self-expandable valves were used 
during the index procedure (0.36% vs. 0.11% balloon 
expandable; p< 0.01). DCO was most likely to occur ≤24h 
after the TAVI procedure (47.4%; n=18); 6 (15.8%) cases 
occurred between 24h and ≤7 days, with the remaining 14 
(36.8%) at ≥60 days. The most frequent presentation was 
cardiac arrest (31.6%; n=12), followed by STEMI (23.7%; 
n=9). The left coronary artery was obstructed in most cases 
(92.1%; n=35). PCI was attempted in the majority of cases 
(74.3% left main; 60% right coronary), and stent 
implantation was successful in 68.8%. Overall in-hospital 
death rate was 50% (n=19), higher if DCO occurred ≤7 
days from the index procedure (62.5% vs 28.6%; p=0.09) 
(Jabbour RJ et al, J Am Coll Cardiol 2018;71:1513–24).  
 
RELEXAO Registry: Thrombus Formation on the 
Device is not Uncommon in Patients With AF Who Are 
Treated by LAA Closure, Strongly Associated With a 
Higher Risk of Ischemic Stroke During Follow-Up 
Among 339 imaged patients of 469 AF patients who 
underwent LAA closure (272 Watchman and 197 
Amplatzer devices), there were 98 major adverse events 
(26 thrombi on devices, 19 ischemic strokes, 2 transient 
ischemic attacks, 18 major hemorrhages, 33 deaths) 
recorded in 89 patients over 13 ± 13 months. The incidence 
of device-related thrombus in patients with LAA imaging 
was 7.2% per year. Older age (hazard ratio - HR: 1.07 per 
1-year increase; p=0.02) and history of stroke (HR: 3.68; 
p=0.03) were predictors of thrombus formation on the 
devices, whereas dual antiplatelet therapy (HR: 0.10; 
p=0.03) and oral anticoagulation at discharge (HR: 0.26; 
p=0.02) were protective factors. Thrombus on the device 
(HR: 4.39; p=0.04) and vascular disease (HR: 5.03; 
p=0.01) were independent predictors of ischemic strokes 
and TIAs during follow-up (Fauchier L et al, J Am Coll 
Cardiol 2018;71:1528-36).   
LAA Occlusion: A Reasonable Option for Stroke 
Prevention in High-Risk Patients With Atrial 
Fibrillation Ineligible for Anticoagulation, but 
Procedural Complication Rates are not Insignificant, 
and Patients Remain at Risk of Serious Adverse Events 
and Death Even After Successful Implant  
Of 143 referrals, 83 patients (aged 76±8 years, 32.5% 
female, mean CHAD2S2-VASc score 4±1) were offered 
LAA occlusion with 80 (95.3%) having had previous 
major bleeding (59% intracranial). LAA occlusion with an 
Amulet device was successful in 82 (98.8%), with 
periprocedural major adverse events occurring in 5 (6%) 
patients (2 device embolizations including 1 death, 2 major 
bleeds). Cardiac imaging in 75 (94%) patients at 2 months 
showed device-related thrombus in 1 case (1.3%) and 
minor (<5mm) device leaks in 13 (17.1%). Over a median 
of 12 months, 3 (3.8%) ischemic strokes, 2 (2.5%) 
hemorrhagic strokes and 5 (6.3%) major extracranial 
bleeds occurred. All-cause mortality was 10%, with most 
deaths (7, 87.5%) due to non-cardiovascular causes 
(Masood A et al, Heart 2018;104:594-9). 
 
Brugada Syndrome: Dynamic Substrate Variability / 
Substrate Size Independently Associated With 
Arrhythmia Inducibility /Substrate Ablation Confers 
ECG Normalization & No Arrhythmia Reinducibility 
Among 191 patients with (group 1; n=88) and without 
(group 2; n=103) Brugada syndrome–related symptoms 
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undergoing electrophysiological study and substrate 
mapping or ablation, before ajmaline testing, 53.4% of 
patients had ventricular tachyarrhythmia inducibility, 
more frequent in group 1 (65.9%) than in group 2 (42.7%; 
p< 0.001). Larger substrates with more fragmented long-
duration ventricular potentials were found in patients with 
inducible arrhythmias than in patients without inducible 
arrhythmias (p< 0.001). After ajmaline, patients without 
arrhythmia inducibility had arrhythmia inducibility 
without a difference in substrate characteristics between 
the 2 groups. The substrate size was the only independent 
predictor of inducibility (odds ratio: 4.51, p< 0.001). A 
substrate size of 4 cm2 best identified patients with 
inducible arrhythmias. Substrate ablation prevented 
ventricular tachyarrhythmia re-inducibility (Pappone C et 
al, J Am Coll Cardiol 2018;71:1631-46).  
Multicenter Registry: Myocarditis After Immune 
Checkpoint Inhibitor (ICI) Therapy May Be More 
Common Than Appreciated, Occurs Early After 
Starting Treatment, Has a Malignant Course, and 
Responds to Higher Steroid Doses  
Of all 964 patients started on ICI, there were 35 
patients with ICI-associated myocarditis (aged 65±13 
years, 29% female, 54% with no other immune-related side 
effects), who were compared to a random sample of 105 
ICI-treated patients without myocarditis. The prevalence 
of myocarditis was 1.14% with a median time of onset of 
34 days after starting ICI. Relative to controls, 
combination ICI (34% vs 2%; p< 0.001) and diabetes (34% 
vs 13%; p=0.01) were more common in cases. Over a 
median of 102 days, 16 (46%) developed major adverse 
cardiovascular events (MACE) (cardiovascular death, 
cardiogenic shock, cardiac arrest, and hemodynamically 
significant complete heart block); 38% of MACE occurred 
with normal ejection fraction. There was a 4-fold increased 
risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 
4.0; p=0.003). Steroids were administered in 89%, and 
lower steroids doses were associated with higher residual 
troponin and higher MACE rates (Mahmood SS et al, J Am 
Coll Cardiol 2018;71:1755-64).   
Electrical Storm (ES) in ICD Patients: The 
Combination of IV Amiodarone and Oral Propranolol 
is Safe, Effective, and Superior to the Combination of 
IV Amiodarone and Oral Metoprolol  
Among 60 ICD patients (45 men, age 65.0 ± 8.5 years) 
with ES, randomized to either propranolol (160 mg/24h, 
Group A) or metoprolol (200 mg/24h, Group B), combined 
with IV amiodarone for 48h, those on propranolol (n=30) 
presented a 2.67 times decreased incidence rate (rate ratio: 
0.375; p=0.001) of ventricular arrhythmic events and a 
2.34 times decreased rate of ICD discharges (rate ratio: 
0.428; p=0.004) during the ICU stay, after adjusting for 
age, sex, ejection fraction, NYHA class, heart failure type, 
arrhythmia type, and arrhythmic events before ICU 
admission. At the end of the first 24-h treatment period, 27 
of 30 (90%) patients in group A, while only 16 of 30 
(53.3%) patients in group B were free of arrhythmic events 
(p=0.03). The termination of arrhythmic events was 77.5% 
less likely in Group B compared with Group A (hazard 
ratio: 0.225, p< 0.001). Time to arrhythmia termination 
and length of hospital stay were significantly shorter in the 
propranolol group (p< 0.05 for both) (Chatzidou S et al, J 
Am Coll Cardiol 2018;71:1897-1906).  
CECCY Trial: With a Lower Than Expected Incidence 
of Anthracycline Cardiotoxicity With Contemporary 
Moderate to High Doses, Prophylactic Carvedilol Had 
no Impact on the Incidence of Early Onset of LVEF 
Reduction / However, Carvedilol Significantly 
Reduced Troponin and Diastolic Dysfunction  
Among 200 patients with HER2-negative breast 
cancer and normal left ventricular ejection fraction 
(LVEF) referred for anthracycline therapy (240 mg/m2), 
who were randomized to carvedilol or placebo until 
chemotherapy completion, the primary endpoint 
(prevention of a ≥10% reduction in LVEF at 6 months) 
occurred in 14 patients (14.5%) in the carvedilol group and 
13 patients (13.5%) in the placebo group (p=1.0). No 
differences in changes of LVEF or B-type natriuretic 
peptide were noted between groups. A significant 
difference existed between groups in troponin I levels over 
time, with lower levels in the carvedilol group (p=0.003). 
Additionally, a lower incidence of diastolic dysfunction 
was noted in the carvedilol group (p=0.039) (Avilla MS et 
al, J Am Coll Cardiol 2018;71:2281-90.   
Genetic Etiology for Alcoholic Cardiomyopathy 
(ACM): Titin Truncating Variants (TTNtv) Represent 
a Prevalent Genetic Predisposition for ACM, 
Associated With a Worse LVEF 
Among 141 ACM cases, 716 dilated CM (DCM) cases, 
and 445 healthy volunteers, variants in well-characterized 
DCM-causing genes were more prevalent in patients with 
ACM than control subjects (13.5% vs 2.9%; p=1.2×10−5), 
but similar between patients with ACM and DCM (19.4%; 
p=0.12) and with a predominant burden of titin truncating 
variants (TTNtv) (9.9%). Separately, an interaction was 
identified between TTN genotype and excess alcohol 
consumption in a cohort of DCM patients not meeting 
ACM criteria. On multivariate analysis, DCM patients 
with a TTNtv who consumed excess alcohol had an 8.7% 
absolute reduction in ejection fraction (LVEF) (p< 0.007) 
compared with those without TTNtv and excess alcohol 
consumption. The presence of TTNtv did not predict 
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phenotype, outcome, or functional recovery on treatment 
in ACM patients (Ware JS C et al, J Am Coll Cardiol 
2018;71:2293-2302.   
Better Clinical Outcomes of His Bundle Pacing (HBP) 
Compared to Right Ventricular Pacing (RVP) 
HBP was successful in 304 of 332 (92%) consecutive 
patients (92%), whereas 433 patients underwent RVP. The 
primary endpoint of death, heart failure hospitalization 
(HFH), or upgrade to biventricular pacing (BiVP) was 
significantly reduced in the HBP group (25% vs 32%; 
hazard ratio -HR: 0.71; p=0.02). This difference was 
observed primarily in patients with ventricular pacing 
>20% (25% in HBP vs 36% in RVP; HR: 0.65; p=0.02). 
The incidence of HFH was significantly reduced in HBP 
(12.4% vs 17.6%; HR: 0.63; p=0.02). There was a trend 
toward reduced mortality in HBP (17.2% vs 21.4%, 
p=0.06) (Abdelrahman M et al, J Am Coll Cardiol 
2018;71:2319-30).   
DEFENSE-PFO: PFO Closure in Patients With High-
Risk PFO Characteristics Resulted in a Lower Rate of 
the Primary Endpoint as Well as Stroke Recurrence 
Among 120 patients with cryptogenic stroke (mean 
age: 51.8 years) randomized to PFO closure or medical 
therapy, the primary endpoint (stroke, vascular death, or 
major bleeding during 2 years of follow-up) occurred 
exclusively in the medication-only group (6 of 60 patients; 
2-year event rate: 12.9%, p=0.013; 2-year rate of ischemic 
stroke: 10.5%, p=0.023). The events in the medication-
only group included ischemic stroke (n=5), cerebral 
hemorrhage (n=1), major bleeding (n=2), and TIA (n=1). 
Nonfatal procedural complications included development 
of atrial fibrillation (n=2), pericardial effusion (n=1), and 
pseudoaneurysm (n=1) (Lee PH et al, J Am Coll Cardiol 
2018;71:2335-42).   
Risk of Endocarditis: Several Invasive Nondental 
Medical Procedures are Associated With a Markedly 
Increased Risk for Infective Endocarditis / Health Care 
Professionals Performing Particularly Risk-Prone 
Procedures Should Consider Every Possible Preventive 
Measure to Decrease the Excess Risk  
Analysis of 7,013 cases of infective endocarditis in 
Sweden indicated that among others, several 
cardiovascular procedures, especially coronary artery 
bypass grafting (CABG); procedures of the skin and 
management of wounds; transfusion; dialysis; bone 
marrow puncture; and some endoscopies, particularly 
bronchoscopy, were strongly associated with an increased 
risk for infective endocarditis. For example, the relative 
risk (RR) was 6 for arterial puncture, 16 for bronchoscopy, 
4.4 for cystoscopy, 4.2 for coronary angiography, 3.5 for 
PCI, ~10 for other CV procedures (EPS, IVUS), ~14 for 
CABG, etc. (Janszky I et al, J Am Coll Cardiol 2018; 
71:2744-52).   
CVD-REAL: Sodium-Glucose Cotransporter-2 
Inhibitors (SGLT-2i) Conferred Lower Risk of Death 
and Heart Failure (HF) Regardless of Pre-Existing 
Cardiovascular Disease (CVD)  
Among153,078 propensity score matched patients 
with diabetes (T2D) (13% with established CVD), 
initiation of an SGLT-2i was associated with lower risk of 
death in patients with and without CVD compared to other 
glucose-lowering drugs (HR: 0.56 and 0.56, respectively). 
There were also associations between SGLT-2i and lower 
risk of heart failure (HF) (HR: 0.72 and 0.61, respectively) 
and the composite of HF or death (HR: 0.63 and HR: 0.56, 
respectively) observed in patients with and without 
established CVD (Cavender MA et al, J Am Coll Cardiol 
2018;71:2497-2506)  
CVD-REAL 2: Sodium-Glucose Cotransporter-2 
Inhibitors (SGLT-2i) in Patients with Diabetes (T2D) 
Conferred Lower Risk of Cardiovascular (CV) Events  
After propensity-matching, there were 235,064 
episodes of treatment initiation in each group; ∼27% had 
established CV disease. Dapagliflozin, empagliflozin, 
ipragliflozin, canagliflozin, tofogliflozin, and luseo-
gliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of 
exposure time in the SGLT-2i group, respectively. Use of 
SGLT-2i vs old glucose-lowering drugs (oGLDs) was 
associated with a lower risk of death (HR: 0.51, p< 0.001), 
heart failure hospitalization (HHF) (HR: 0.64, p=0.001), 
death or HHF (HR: 0.60, p< 0.001), MI (HR: 0.81, p< 
0.001), and stroke (HR: 0.68, p< 0.001). Results were 
directionally consistent across both countries and patient 
subgroups, including those with and without CV disease 
(Kosiborod M et al, J Am Coll Cardiol 2018;71:2628-39).   
Cocaine and/or Marijuana Use is Present in 10% of 
Patients With an MI at Age≤50 Years and is Associated 
With Worse All-Cause and Cardiovascular Mortality  
Among 2,097 MI patients (age 44.0±5.1 years, 19.3% 
female, 73% white), cocaine and/or marijuana was used by 
224 (10.7%); cocaine by 99 (4.7%), and marijuana by 125 
(6.0%). Individuals with substance use had significantly 
lower rates of diabetes (14.7% vs 20.4%, p=0.05) and 
hyperlipidemia (45.7% vs 60.8%, p< 0.001), but they were 
significantly more likely to use tobacco (70.3% vs 49.1%, 
p< 0.001). Over a median of 11.2 years, use of cocaine and/ 
or marijuana was associated with significantly higher 
cardiovascular mortality (hazard ratio-HR: 2.22, p=0.005) 
and all-cause mortality (HR: 1.99, p=0.001) (DeFilippis 
EM et al, J Am Coll Cardiol 2018;71:2540-51)  
 68 
 
 
MANAGE Trial: Among Patients who Had 
Myocardial Injury after Non-Cardiac Surgery (MINS), 
Dabigatran 110 mg bid Lowered Risk of Major 
Vascular Complications, with no Significant Increase 
in Major Bleeding 
Among 1754 patients with MINS randomly assigned to 
dabigatran (n=877) or placebo (n=877) (556 also 
randomized to omeprazole), the composite primary 
efficacy outcome (major vascular complication) occurred 
in fewer patients randomized to dabigatran than placebo 
(11% vs 15%; hazard ratio - HR 0.72, p=0.0115). The 
primary safety composite outcome (major bleeding) 
occurred in 3% in the dabigatran and 4% in the placebo 
group (HR 0.92, p=0.76) (Devereaux PJ et al, Lancet 
2018;391:2325-34).  
RADIANCE-HTN SOLO: Compared With a Sham 
Procedure, Endovascular Ultrasound Renal 
Denervation Reduced Ambulatory Blood Pressure at 2 
Months in Patients With Combined Systolic–Diastolic 
Hypertension in the Absence of Medications  
Among 146 patients randomized to undergo renal 
denervation (n=74) or a sham procedure (n=72), the 
reduction in daytime ambulatory systolic blood pressure 
was greater with renal denervation (−8.5+9.3 mmHg) than 
with the sham procedure (−2.2+10 mmHg; baseline-
adjusted difference between groups: −6.3 mmHg, 
p=0.0001). No major adverse events were reported in 
either group (Azizi M JL et al, Lancet 2018;391:2335-45).  
SPYRAL HTN-ON MED: Renal Denervation in the 
Main Renal Arteries and Branches Significantly 
Reduced Blood Pressure (BP) Compared With Sham 
Control With no Major Safety Events / Incomplete 
Medication Adherence was Common 
Among 80 patients randomly assigned to renal 
denervation (n=38) and sham control (n=42), office and 24 
h ambulatory BP decreased significantly from baseline to 
6 months in the renal denervation group (mean baseline-
adjusted treatment differences in 24 h systolic BP −7.0 mm 
Hg, p=0.0059, 24 h diastolic BP −4.3 mmHg, p=0.0174, 
office systolic BP −6.6 mm Hg, p=0.0250, and office 
diastolic BP −4.2 mm Hg, p=0.0190). The change in BP 
was significantly greater at 6 months in the renal 
denervation group than the sham-control group for office 
systolic BP (difference −6.8 mm Hg, p=0.0205), 24 h 
systolic BP (difference −7.4 mmHg, p=0.0051), office 
diastolic BP (difference −3·5 mmHg, p=0.0478), and 24 h 
diastolic BP (difference −4·1 mm Hg, p=0.0292). 
Evaluation of hourly changes in 24 h systolic and diastolic 
BP showed BP reduction throughout 24 h for the renal 
denervation group. 3-month BP reductions were not 
significantly different between groups. Medication 
adherence was about 60% and varied for individual 
patients throughout the study. No major adverse events 
were recorded in either group (Kandzari DE et al, Lancet 
2018;391:2346-55).   
DIVA Trial: In Patients Undergoing Stenting of 
Saphenous Vein Graft (SVG) Lesions, no Significant 
Differences in Outcomes Between DES and BMS at 1 
Year / The Lower-Cost BMS Can be Used in SVG 
Lesions Without Compromising Safety or Efficacy  
Among 597 patients (aged 68.6+7.6 years, 99% men) 
randomly assigned to drug eluting stents (DES) (n=292) or 
bare metal stents (BMS) (n=305), at 1 year, the incidence 
of target vessel failure was 17% in the DES group vs 19% 
in the BMS group (adjusted hazard ratio 0.92, p=0.70). 
Between-group differences in the components of the 
primary endpoint, serious adverse events, or stent 
thrombosis were not significant. Enrolment was stopped 
before the revised target sample size of 762 patients was 
reached (Brilakis ES et al, Lancet 2018; 391:1997-2007).   
Meta-Analysis: In Selected Patients With Cryptogenic 
Stroke, PFO Closure is Superior to Medical Therapy 
for Prevention of Further Stroke, Particularly so for 
Patients With Moderate-To-Large Shunts 
Meta-analysis of 5 studies (3440 patients: 1829 
randomized to device closure and 1611 to medical therapy) 
indicated that across all patients, PFO closure was superior 
to medical therapy for prevention of stroke (hazard ratio - 
HR 0.32, p= 0.018, I2 = 73.4%). The risk of AF was 
significantly increased with device closure (risk ratio - RR 
4.68, p<0.001, heterogeneity I2 = 27.5%). In patients with 
large shunts, PFO closure was associated with a significant 
reduction in stroke (HR 0.33; p = 0.005), whilst there was 
no significant reduction in stroke in patients with a small 
shunt (HR 0.90, p = 0.712). There was no effect from the 
presence or absence of an atrial septal aneurysm on 
outcomes (P = 0.994) (Ahmad Y et al, Eur Heart J 
2018;39:1638-49).  
Meta-Analysis: PFO Closure Confers Significant 
Reduction in Risk of Stroke vs Medical Management at 
the Expense of Increased Risk of Atrial Arrhythmias  
Pooled analysis of 5 RCTs investigating 3630 PFO 
patients with cryptogenic stroke revealed that device 
closure compared to medical management was associated 
with a significant reduction in stroke (RR=0.3). There was, 
however, a significant increase in atrial arrhythmias with 
device therapy (RR=4.8). There was no increase in 
bleeding (RR=0.80), death (RR=0.76) or “any adverse 
events” (RR=1.02) with device therapy. Sub-group 
analysis revealed that device closure significantly reduced 
the incidence of the composite primary endpoint among 
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patients who had moderate to large shunt sizes (RR=0.22) 
(Riaz H et al, Am Heart J 2018;199:44-50).   
Meta-Analysis: Compared with Triple (TAT), Double 
Antithrombotic Therapy (DAT) Shows a Reduction in 
Bleeding by 47% with Comparable Outcomes of 
MACE / DAT May be a Better Option than TAT in 
Many Patients with AF Following PCI 
Meta-analysis of 4 trials including 5317 patients with 
AF undergoing PCI, of whom 3039 (57%) received DAT, 
showed that compared with the TAT arm, TIMI major or 
minor bleeding showed a reduction by 47% in the DAT 
arm (4.3% vs 9%; hazard ratio-HR 0.53, I2 = 42.9%). In 
addition, there was no difference in major adverse cardiac 
events (MACE) (10.4% vs 10%, HR 0.85, I2 = 58.4%), or 
in individual outcomes of all-cause mortality, cardiac 
death, MI, stent thrombosis, or stroke between the two 
arms (Golwala HB et al, Eur Heart J 2018;39:1726-35a).   
Meta-Analysis: Outcomes in Patients with Angina 
Without Obstructive CAD are Worse in Patients With 
a Higher Burden of Cardiovascular Risk Factors, 
‘Some’ Coronary Atherosclerosis, Typical Angina, and 
Well-Documented Myocardial Ischemia 
Meta-analysis of 54 studies, reporting outcomes in 
overall 35,039 patients (mean age 56, male/female ratio 
0.51) with angina and no obstructive CAD, showed that 
after a median of 5 years, the pooled incidence of the 
primary outcome (death and MI) was 0.98/100 person-
years, with considerable heterogeneity among studies 
(I2 = 91%, p < 0.001). The primary outcome was 
associated with prevalent dyslipidemia (P = 0.016), 
diabetes (P = 0.035), and hypertension (P = 0.016). Studies 
enrolling patients with less-than-obstructive CAD showed 
a higher incidence of the primary outcome (1.32/100 
person-years) compared with studies including only 
patients with ‘entirely normal’ coronary arteries (0.52/100 
person-years, respectively; p < 0.01). Ischemia 
documented by non-invasive imaging techniques was 
associated with a higher incidence of events (p = 0.02). 
Overall, these patients, however, suffered from a high 
incidence of recurrent hospitalization (Radico F et al, Eur 
Heart J 2018;39:2135-46).  
Patients with Heart Failure with Reduced Ejection 
Fraction (HFrEF) Taking Carvedilol Had Improved 
Survival as Compared to Metoprolol  
A total of 43,941 metoprolol patients were matched 
with as many carvedilol patients. The adjusted hazard ratio 
of mortality for metoprolol succinate compared to 
carvedilol was 1.069 (p < 0.001). At 6 years, the survival 
probability was higher in the carvedilol group compared to 
the metoprolol group (55.6% vs 49.2%, p < 0.001). The 
sub-group analyses show that the results hold true 
separately for male, over or under 65 years old, therapy 
duration >3 months and non-diabetic patients (Ajam T et 
al, Am Heart J 2018;199:1-6).   
Important Review and Other Articles   
● 2018 ESC Guidelines for the diagnosis and management of 
syncope (Brignole M et al, Eur Heart J 2018;39:1883-1948)   
● Cardiovascular imaging for the athlete’s heart (Pelliccia A et 
al, Eur Heart J 2018;39: 1949-69)  
● Expert Consensus Document on Takotsubo syndrome, Part I 
& II (Ghadri J-R et al, Eur Heart J 2018;39:2032-62)  
● Acute Coronary Syndromes with Normal or Non-Obstructive 
Coronary Arteries (ACSNNOCA) (Manolis AS et al, Trends 
Cardiovasc Med 2018 May 23; doi: 10.1016/j.tcm.2018.05.006)  
● Obesity (Gadde KM et al, J Am Coll Cardiol 2018;71:69-84)  
● Ultrasound for lower extremity deep venous thrombosis 
(Needleman L et al, Circulation 2018;137:1505-1515  
● Leptin-Aldosterone-Neprilysin Axis (Packer M, Circulation 
2018;137:1614–1631)   
● Thyroid hormones and cardiovascular function and diseases 
(Razvi S et al, J Am Coll Cardiol 2018;71:1781-96 )  
● Cerebrovascular events after cardiovascular procedures 
(Devgun JK et al, J Am Coll Cardiol 2018;71:1910-20)  
● Psychopharmacology and cardiovascular disease (Pina IL et 
al, J Am Coll Cardiol 2018;71:2346–59)   
● Chronic thromboembolic pulmonary hypertension (Mahmud 
E et al, J Am Coll Cardiol 2018;71:2468-86)    
● 2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus on 
Optimal Use of Ionizing Radiation in Cardiovascular Imaging: 
Best Practices for Safety and Effectiveness (Hirshfeld JW et al, 
J Am Coll Cardiol 2018;71: e283–351)   
● Anthracycline cardiotoxicity (Henriksen PA, Heart 
2018:104:971-77)   
● ECG screening in athletes (Lampert R, Heart 2018;104:1037-
43)   
● Myocardial biopsy (Francis R & Lewis C, Heart 
2018;104:950-8)  
● Constrictive pericarditis (Welch TD, Heart 2018;104:725-31)  
● PCSK-9 inhibitors (Landmesser U et al, Eur Heart J 
2018;39:1131-43)  
● 2018 EHRA Guide on use of NOACs in AF patients (Steffel J 
et al, Eur Heart J 2018;39:1330-93)  
● Electrical cardiac injuries (Waldmann V et al, Eur Heart J 
2018;39:1459-65)  
● High altitude exposure (Parati G et al, Eur Heart J 2018;39:  
● Re-innervation post-heart transplantation (Grupper A et al, 
Eur Heart J 2018;39:1799-1806) 
